Search

Your search keyword '"Nokihara H"' showing total 369 results

Search Constraints

Start Over You searched for: Author "Nokihara H" Remove constraint Author: "Nokihara H"
369 results on '"Nokihara H"'

Search Results

1. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

8. 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)

14. P1.01-32 A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease

17. OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations

18. MA 16.04 Phase II Trial of S-1 Treatment as Palliative-Intent Chemotherapy for Previously Treated Advanced Thymic Carcinoma

19. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)

20. Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma

22. 430P Comparison of multimodality therapy in clinical stage IIIAN2 non-small cell lung cancer: consecutive analysis of surgery, radiotherapy, chemotherapy and their combination

23. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study

25. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment

28. 449P Distribution of erlotinib to brain, tumor lesion and normal tissue analyzed by matrix assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry

29. 447P Efficacy of platinum-doublet chemotherapy for patients with lung cancer with epidermal growth factor receptor (EGFR) activating mutation after the failure of EGFR-tyrosine kinase inhibitors (TKIs) treatment

30. 372PD Reduction in nephrotoxicities using short hydration in chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies

31. 467P Efficacy of cranial radiotherapy prior to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients with brain metastases

32. 420O - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)

34. 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

39. A Phase 1 Study of Veliparib (Abt-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Non-Small Cell Lung Cancer (Nsclc)

40. Evaluation of Safety, Tolerability, Pharmacokinetics and Efficacy of Dabrafenib, a Braf Inhibitor, in Japanese Patients with Braf V600 Mutation-Positive Advanced Solid Tumors: a Phase I Study

41. Phase I Study of Anti-Pd-1 Antibody Ono-4538 and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

42. Oral Hydration As a Post-Hydration Method for Cisplatin (Cddp) Administration in Patients with Lung Cancer: a Prospective Multicenter Trial

43. Impact of Kras Mutation on the Response and Prognosis of Patients with Stage III Non-Squamous Non-Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources